Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch
A Study of Nalbuphine Extended-release (NAL ER) Oral Tablets in Subjects With Impaired Hepatic Function Compared to Healthy Subjects and Exploratory Effect on Itch
Sponsor: Syneos Health
A PHASE1 clinical study on Hepatic Impairment and Nalbuphine, this trial is ongoing. The trial is conducted by Syneos Health and has accumulated 11 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jul 2020 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Sep 2019 — Mar 2020 [monthly]
Suspended PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Suspended PHASE1
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Syneos Health
- Trevi Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .